Livingston, New Jersey Clinical Trials

A listing of Livingston, New Jersey clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 54 clinical trials
Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer

This phase II trial compares high-dose rate brachytherapy and stereotactic ablative radiotherapy as monotherapy in treating patients with prostate cancer that has not spread to other parts of the body (localized). High-dose rate brachytherapy delivers radiation directly into the prostate within a few minutes by a single radioactive seed through …

treatment regimen
bone scan
androgen deprivation therapy
cancer
prostate specific antigen
Rutgers New Jersey Medical School
 (8.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +1 other locations
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated Nonsquamous NSCLC

This is a Phase 2, randomized, multicenter, double-blind study of the glutaminase inhibitor telaglenastat with standard-of-care pembrolizumab and chemotherapy versus placebo with standard-of-care pembrolizumab and chemotherapy for first line treatment of metastatic disease in patients with KEAP1/NRF2-mutated, stage IV, nonsquamous, non-small cell lung cancer (NSCLC). The study primary endpoints are …

LKB1
EGFR
proto-oncogene tyrosine-protein kinase ros
stage iv non-small cell lung cancer
adjuvant
New Jersey Cancer Care and Blood Disorders (NJCCBD)
 (8.1 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +27 other locations
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. It is the most common form of lung cancer, accounting for around 85% of lung cancers. The purpose of this study is to evaluate the safety and efficacy …

EGFR
lung cancer
epidermal growth factor
erbb1
cancer
Overlook Medical Center /ID# 219108
 (5.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +38 other locations
TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer

This phase II trial studies how well TAS-102 and oxaliplatin work in treating patients with stage IV colon cancer. Drugs used in chemotherapy, such as TAS-102 and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or …

EGFR
cancer chemotherapy
colorectal cancer
chemotherapy regimen
stage iva colon cancer
Saint Barnabas Medical Center
 (0.6 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +1 other locations
Suicide Prevention for Patients With Chronic Pain

Patients with chronic pain and moderate suicide risk (n=60) will be randomized to receive remote-PST or remote-supportive psychotherapy. We will assess problem-solving deficits through self-report, objective neuropsychological assessment and caregiver report. We have used an adaptive design so that if there is strong evidence for target engagement, we will continue …

chronic pain
suicidal
amplified musculoskeletal pain syndrome
suicide
chronic widespread pain
VA NJHCS
 (5.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • 1 location
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI  

The objective of the proposed work is to determine whether administration for 12 months of romosozumab followed by 12 months of denosumab will maintain bone mass at the knee in subjects with subacute SCI compared to 24 months of denosumab administration alone.

Kessler Institute for Rehabilitation
 (4.3 away)
  • 0 views
  • 14 Mar, 2022
  • +1 other locations
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI test  

The objective of the proposed work is to determine whether administration for 12 months of romosozumab followed by 12 months of denosumab will maintain bone mass at the knee in subjects with subacute SCI compared to 24 months of denosumab administration alone.

Accepts healthy volunteers
Kessler Institute for Rehabilitation
 (4.3 away)
  • 0 views
  • 14 Mar, 2022
  • +1 other locations
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The …

deficiency
gaucher disease
imiglucerase
eliglustat
Investigational Site Number 840099
 (8.4 away) Contact site
  • 0 views
  • 04 Dec, 2020
  • +208 other locations
Mucopolysaccharidosis I (MPS I) Registry

The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients …

Investigational Site Number 840099
 (8.4 away) Contact site
  • 0 views
  • 04 Dec, 2020
  • +124 other locations
Pompe Disease Registry

The Pompe Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Pompe disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The objectives …

replacement therapy
gaa gene
deficiency
glycogen storage disease type ii
myozyme
Investigational Site Number 840099
 (8.4 away) Contact site
  • 0 views
  • 22 Dec, 2020
  • +168 other locations